Revolution Medicines, Inc. (RVMD)
Stock Price:
$31.01 USD
-1.54 (-4.73%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.83B |
| Revenue (ttm) |
48.42M |
| Net Income (ttm) |
n/a |
| Shares Out |
59.01M |
| EPS (ttm) |
-21.25 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$31.01 |
| Previous Close |
$32.55 |
| Change ($) |
-1.54 |
| Change (%) |
-4.73% |
| Day's Open |
33.03 |
| Day's Range |
30.82 - 33.03 |
| Day's Volume |
59,909 |
| 52-Week Range |
17.35 - 47.14 |
More Stats
| Market Cap |
1.83B |
| Enterprise Value |
1.49B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
59.01M |
| Float |
31.13M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-21.25 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.51M |
| Short Ratio |
10.86 |
| Short % of Float |
5.98% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
37.79 |
| PB Ratio |
5.37 |
| Revenue |
48.42M |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
337.47M |
| Net Cash / Share |
5.72 |
| Gross Margin |
-86.15% |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-17.30% |
| ROE |
-38.26% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
4 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$44.25*
(42.70% upside)
Low
32.0
Current: 31.01
High
55.0
Target: 44.25
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 50.04 | 20.17 | - |
| Revenue Growth | 148.16% | - | - |
| Gross Profit | 50.04 | 20.17 | - |
| Operating Income | -54.12 | -40.33 | -31.13 |
| Net Income | -47.66 | -41.79 | -31.13 |
| Shares Outstanding | 2.77 | 2.30 | 1.72 |
| Earnings Per Share | -22.33 | -21.24 | -20.25 |
| Operating Cash Flow | -49.62 | 1.21 | -25.15 |
| Capital Expenditures | -2.39 | -1.50 | -1.58 |
| Free Cash Flow | -52.01 | -0.29 | -26.72 |
| Cash & Equivalents | 123 | 69.80 | 9.08 |
| Net Cash / Debt | 123 | 69.80 | 9.08 |
| Assets | 221 | 171 | 15.08 |
| Liabilities | 67.99 | 73.93 | 10.55 |
| Book Value | -153 | -108 | -67.72 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Revolution Medicines, Inc. |
| Country |
United States |
| Employees |
100 |
| CEO |
Mark A. Goldsmith |
Stock Information
| Ticker Symbol |
RVMD |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: RVMD |
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit targets primarily within the RAS and mTOR signaling pathways. The company's principal product candidate is RMC-4630, an inhibitor of SHP2, which is in Phase 1b/2 study for the treatment of RAS-dependent tumors. Its products in preclinical stage include mutant RAS proteins; SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a mTORC1 inhibitor. Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors. The company was founded in 2014 and is headquartered in Redwood City, California.